Special Issue "Advancements and Challenges of Intrapleural and Peritoneal Drug Delivery"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmaceutical Technology".

Deadline for manuscript submissions: 26 April 2024 | Viewed by 1534

Special Issue Editors

Department of Surgery, Petrus-Hospital Wuppertal, 42283 Wuppertal, Germany
Interests: pleural and peritoneal surface malignancies; experimental pharmacology; experimental surgery; epidemiology; nanotechnology
Department of Biochemistry and Molecular Biology, University of Environmental and Life Sciences, Wroclaw, Poland
Interests: peritoneal surface malignances; experimental pharmacology; molecular biology of cancer
Department of Surgery, University-Hospital Düsseldorf, University of Düsseldorf, Düsseldorf, Germany
Interests: peritoneal metastasis; colorectal carcinomas; experimental surgery, surgical oncology, pleural malignancies

Special Issue Information

Dear Colleagues,

Clinically, intracavitary drug delivery systems are gaining more relevance every year. Due to their broad application in a wide range of indications, new and improved concepts are constantly presented and reviewed. These include the management of patients with pleural and peritoneal cancer, malignant effusions, peritonitis, pleuritis or even intraperitoneal dialyses. Significantly, for physicians, these diseases are among the most challenging to treat. For intraperitoneal applications targeting carcinomas, there is a wide range of concepts, including hyperthermic intraperitoneal chemotherapy (HIPEC), Pressurized intraperitoneal chemotherapy (PIPAC), Hyperthermic Nano Aerosol therapy (HINAT), Foam-based intraperitoneal chemotherapy (FBIC) and Gas-based intraperitoneal hyperthermia (GIH) and locoregional nanochemotherapy.

Nevertheless, these applications consist of fundamental theories and concepts which may extend to various other body cavities (i.e., the pleural cavity). However, they may also show efficacy in other clinical indications such as intraperitoneal dialyses, peritonitis, pleuritis and the management of malignant pleural effusions. This special edition includes basic as well as advanced concepts of intraperitoneal and pleural drug delivery and covers new developments and management of intraperitoneal and pleural applications.

We especially welcome original articles, case reports and short commentaries on:

  • Peritoneal and pleural drug delivery
  • Concepts of drug delivery (intracavitary)
  • Pharmacological and molecular biological studies with regard to pleural and peritoneal cavity
  • Clinical studies and animal experiments
  • Electron microscopy studies on drug particles for intracavitary delivery
  • Applications related to intraperitoneal and pleural treatments pharmacological and toxicological studies

Dr. Veria Khosrawipour
Dr. Agata Mikolajczyk-Martinez
Dr. Tanja Khosrawipour
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • peritoneal and pleural malignancies
  • intraperitoneal and pleural drug delivery
  • peritoneal dialyses
  • peritonitis, pleuritis
  • hyperthermic intraperitoneal chemotherapy (HIPEC)
  • surface applications
  • colorectal cancer
  • ovarian cancer

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


12 pages, 1856 KiB  
Triple-Therapy of Peritoneal Metastasis—Partial-Dehydration under Hyperthermic Condition Combined with Chemotherapy: The First Preliminary In-Vitro Results
Pharmaceuticals 2023, 16(5), 763; https://doi.org/10.3390/ph16050763 - 18 May 2023
Cited by 1 | Viewed by 1027
A newly introduced combination of intraperitoneal dehydration and hyperthermia has recently been shown to be feasible and cytotoxic for colon cancer cells in vivo. For the first time, our study now aims to evaluate dehydration under hyperthermic conditions combined with chemotherapy for potential [...] Read more.
A newly introduced combination of intraperitoneal dehydration and hyperthermia has recently been shown to be feasible and cytotoxic for colon cancer cells in vivo. For the first time, our study now aims to evaluate dehydration under hyperthermic conditions combined with chemotherapy for potential use in the clinical setting. In this study, in vitro colon cancer cells (HT-29) were subjected to single or several cycles of partial dehydration under hyperthermic conditions (45 °C), followed by chemotherapy (triple exposure) with oxaliplatin or doxorubicin in various configurations. The viability, cytotoxicity, and proliferation of cells after the proposed protocols were assessed. Intracellular doxorubicin uptake was measured via flow cytometry. After one cycle of triple exposure, the viability of HT-29 cells was significantly reduced versus the untreated control (65.11 ± 5%, p < 0.0001) and versus only chemotherapy (61.2 ± 7%, p < 0.0001). An increased chemotherapeutic inflow into the cells after triple exposure was detected (53.4 ± 11%) when compared to cells treated with chemotherapy alone (34.23 ± 10%) (p < 0.001). Partial dehydration in a hyperthermic condition combined with chemotherapy increases the overall cytotoxicity of colon cancer cells significantly compared to chemotherapy alone. This could possibly be related to enhanced intracellular uptake of chemotherapeutic agents after partial dehydration. Further studies are required for the further evaluation of this new concept. Full article
Show Figures

Figure 1

Back to TopTop